HomeAI · summaries
Storia in 3 fonti
Vaderis Therapeutics Announces Oversubscribed $152 Million Series B Financing and Initiation of the Global Phase 3 HEROIC Study of Engasertib for Hereditary Hemorrhagic Telangiectasia
BASEL, Switzerland and LINCOLNSHIRE, Ill., Aug. 11, 2026 /PRNewswire/ -- Vaderis Therapeutics, a clinical-stage biopharmaceutical company focused on developing targeted therapies for rare vascular diseases, today announced the closing of a private $152 million Series B financing
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Vaderis hauls in $152M to test an AKT-targeting drug
The startup is one of at least a few young companies zeroing in on the rare bleeding disorder, hereditary hemorrhagic telangiectasia, with a more precise AKT blocker.
- ·
endpoints.news
Vaderis gets $152M to run Phase 3 of rare bleeding disorder treatment
Vaderis Therapeutics raised a Series B to run a Phase 3 study of its AKT inhibitor engasertib in a rare blood disorder called hereditary hemorrhagic telangiectasia.
